B

BioXcel Therapeutics

D
BTAI
USD
-0.047
(-6.5097%)
Market Closed
9,821.00
Volume
-1.89
EPS
-
Div Yield
-0.195087
P/E
27,502,039.35
Market Cap
Today
-6.5097%
1 Week
0.193%
1 Month
22.772%
6 Months
-71.519%
12 Months
-86.111%
Year To Date
-77.196%
All Time
-93.369%
News

Lagarde Foresees Inflation Return to 2% by 2025

23.09.2024
Economy news

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

AI Stocks Are Booming But Could Be Overvalued Now

16.07.2024
Stocks news

Google Joins Other Tech Giants Flocking to Southeast Asia

03.06.2024
Economy news

Utilities Surge Amid AI Boom

16.05.2024
Stocks news
More
Related Instruments
C
CRSP
1.15
(2.2656%)
USD
E
EDIT
-0.11
(-3.3537%)
USD
N
NTLA
-0.05
(-0.3113%)
USD
S
SGMO
0.33
(13.3603%)
USD
REGN
REGN
-3.78
(-0.4561%)
USD
B
BLUE
-0.0615
(-14.0764%)
USD
MRK
MRK
0.46
(0.4567%)
USD
PFE
PFE
0.105
(0.3839%)
USD
GILD
GILD
6.36
(6.9463%)
USD

Title:
BioXcel Therapeutics

Sector:
Healthcare
Industry:
Biotechnology
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology.The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Do you need help or have a question?
Contact Us